Net sales have increased from 5,699.00 million in DQ-01 to Rs 8,370.00 million in the quarter ended December 31, 2002.
The company has posted a net profit of Rs 6,054.00 million for the year ended December 31, 2002 (FY-02) as compared to Rs 2,533.00 million in the year ended December 31, 2001 (FY-01).
Net sales have increased from Rs 20,262.00 million in FY-01 to Rs 29,249.00 million in FY-02.
Consolidated results are as follows:
The group has posted a net profit of Rs 1,917.00 million in DQ-02. Net sales stood at Rs 11,040.00 million in DQ-02.
The group has posted a net profit of Rs 6,084.00 million for the year ended December 31, 2002 (FY-02) as compared to Rs 2,637.00 million in the year ended December 31, 2001 (FY-01).
Net sales have increased from Rs 27,257.00 million in FY-01 to Rs 38,234.00 million in FY-02.
Commenting on the business results, D S Brar CEO and managing director, Ranbaxy Laboratories Ltd said, "The results have been very encouraging. We have been able to significantly improve our operational effectiveness and financial performance. A sound base has been established to enter into the specialty products segment in key developed markets."
BSE Code: 500359
